NAS:ADMA Key Ratios
| Market Cap $ M | 2,004.66 |
| Enterprise Value $ M | 2,069.12 |
| P/E(ttm) | 12.70 |
| PE Ratio without NRI | 12.59 |
| Forward PE Ratio | 9.93 |
| Price/Book | 4.94 |
| Price/Sales | 4.18 |
| Price/Free Cash Flow | 18.35 |
| Price/Owner Earnings | 18.77 |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 512.00 |
| EPS (TTM) $ | 0.70 |
| Beneish M-Score | -2.41 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | 47.00 |
| EV-to-EBIT | 9.18 |
| EV-to-EBITDA | 8.88 |
| PEG | -- |
| Shares Outstanding M | 223.98 |
| Net Margin (%) | 32.98 |
| Operating Margin % | 42.26 |
| Pre-tax Margin (%) | 42.26 |
| Quick Ratio | 3.81 |
| Current Ratio | 6.97 |
| ROA % (ttm) | 27.24 |
| ROE % (ttm) | 40.13 |
| ROIC % (ttm) | 36.89 |
| Dividend Yield % | -- |
| Altman Z-Score | 6.96 |
ADMA Number of Guru Trades
ADMA Volume of Guru Trades
Gurus Latest Trades with NAS:ADMA
NAS:ADMA is held by these investors
Guru Commentaries on NAS:ADMA
During the quarter we added several new ideas, including Insmed, ADMA Biologics, HealthEquity, Waystar, and Alignment Healthcare. Biotech continues to be a significant weight in the R2500G, and we continue to believe commercial stage companies with marketed products have strong growth prospects. ADMA has unique manufacturing capabilities for plasma-derived therapeutics and should continue to gain market share and drive profitable growth for the next several years.
ADMA Biologics (ADMA) had another outstanding quarter and guided metrics higher. This performance is indicative of the company's strong position within the health care sector, particularly in biotechnology. The positive guidance suggests that ADMA is well-positioned for future growth, aligning with our strategy of investing in high-quality growth companies. The overall performance of our portfolio, which includes ADMA, reflects our focus on companies that exhibit stable, consistent growth and attractive valuations.
News about NAS:ADMA
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
